Evidence map›Paper›PMID 39257773›Full record

ArticlebioRxiv : the preprint server for biology2024

Synaptic imbalance and increased inhibition impair motor function in SMA.

Emily V Fletcher, Joshua I Chalif, Travis M Rotterman, John G Pagiazitis, Meaghan Van Alstyne, Nandhini Sivakumar, Joseph E Rabinowitz, Livio Pellizzoni, Francisco J Alvarez, George Z Mentis

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Emily V FletcherCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.
Joshua I ChalifCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.
Travis M RottermanDepartment of Cell Biology, Emory University, Atlanta, GA, 30322, USA.
John G PagiazitisCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.
Meaghan Van AlstyneCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.
Nandhini SivakumarCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.
Joseph E RabinowitzDepartment of Pharmacology, Center of Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Livio PellizzoniCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.
Francisco J AlvarezDepartment of Cell Biology, Emory University, Atlanta, GA, 30322, USA.
George Z MentisCenter for Motor Neuron Biology and Disease, Columbia University, New York, NY, 10032, USA.ORCID 0000-0002-4610-2016

Funding

Mechanisms of Central Synaptic Dysfunction in SMAR01NS078375 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI George Z Mentis · 2012 to 2026
$6.6M
DEVELOPMENT OF SYNAPTIC INPUTS ON SPINAL INTERNEURONSR01NS047357 · NINDS · WRIGHT STATE UNIVERSITY · PI ALVAREZ, FRANCISCO J · 2004 to 2025
$6.4M
RNA-Mediated Mechanisms of Motor System Dysfunction in Spinal Muscular AtrophyR01NS102451 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Livio Pellizzoni · 2017 to 2026
$3.9M
Mechanisms of synaptic loss by the classical complement pathway in motor circuit development and diseaseR01AA027079 · NIAAA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MENTIS, GEORGE Z · 2018 to 2022
$3.2M
Essential role of Stasimon in motor circuit development and diseaseR01NS114218 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PELLIZZONI, LIVIO · 2020 to 2024
$2.9M
Cellular and Neuronal Circuit Mechanisms Involved in Locomotor ActivityR01NS125362 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI George Z Mentis · 2023 to 2026
$2.5M
Mechanisms and Therapeutic Targeting of Motor Neuron Death in SMAR01NS116400 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PELLIZZONI, LIVIO · 2020 to 2024
$2.3M
NIAAA NIH HHS R01 AA027079NINDS NIH HHS R01 NS047357NINDS NIH HHS R01 NS078375NINDS NIH HHS R01 NS102451NINDS NIH HHS R01 NS114218NINDS NIH HHS R01 NS116400NINDS NIH HHS R01 NS125362
6 · The paper itself

Abstract

Movement is executed through the balanced action of excitatory and inhibitory neurotransmission in motor circuits of the spinal cord. Short-term perturbations in one of the two types of transmission are counteracted by homeostatic changes of the opposing type. Prolonged failure to balance excitatory and inhibitory drive results in dysfunction at the single neuron, as well as neuronal network levels. However, whether dysfunction in one or both types of neurotransmission leads to pathogenicity in neurodegenerative diseases characterized by select synaptic deficits is not known. Here, we used mouse genetics, functional assays, morphological methods, and viral-mediated approaches to uncover the pathogenic contribution of unbalanced excitation-inhibition neurotransmission in a mouse model of spinal muscular atrophy (SMA). We show that vulnerable motor circuits in the SMA spinal cord fail to respond homeostatically to the reduction of excitatory drive and instead increase inhibition. This imposes an excessive burden on motor neurons and further restricts their recruitment to activate muscle contraction. Importantly, genetic or pharmacological reduction of inhibitory synaptic drive improves neuronal function and provides behavioural benefit in SMA mice. Our findings identify the lack of excitation-inhibition homeostasis as a major maladaptive mechanism in SMA, by which the combined effects of reduced excitation and increased inhibition diminish the capacity of premotor commands to recruit motor neurons and elicit muscle contractions.

Identifiers

PMID39257773
PMCPMC11383993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.